Thousands more vulnerable people are eligible to receive the UK’s second antiviral Paxlovid, which has been added to the PANORAMIC national study.
Thousands more vulnerable people are eligible to receive the UK’s second antiviral Paxlovid, which has been added to the PANORAMIC national study.